Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 115,935

Document Document Title
WO/2024/023266A1
The present invention relates to novel compounds for the treatment, alleviation or prevention of a group of diseases, disorders and abnormalities which are responsive to the modulation or inhibition of the activation of a component of th...  
WO/2024/023129A1
The invention relates to novel compounds having the general formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein, composition including the compounds and methods of using the compounds.  
WO/2024/024962A1
The present invention relates to a therapeutic agent and/or a prophylactic agent for central nervous system diseases associated with abnormal aggregates of brain proteins, the therapeutic agent and/or the prophylactic agent containing, a...  
WO/2024/022234A1
A use of a compound represented by formula (I) in the preparation of a drug for treating BTK-related diseases comprising diseases of the central nervous system, which belongs to the technical field of chemistry in medicine. The compound ...  
WO/2024/017863A1
The invention relates to novel compounds having the general formula (I) wherein R4, R5, X1, X2, X3 and Y1 are as described herein, composition including the compounds and methods of using the compounds.  
WO/2024/017856A1
The invention relates to novel compounds having the general formula I wherein R1, R2, X1, X2,X3 and W are as described herein, composition including the compounds and methods of using the compounds.  
WO/2024/020517A1
Provided herein are compounds of formula (II) and formula (I) that are inhibitors of QPCTL and QPCT: (II) & (I) Also provided are pharmaceutical compositions comprising the compounds, as well as the compounds for use in methods for the t...  
WO/2024/019603A1
The present invention relates to a protein for preventing or treating brain-nervous system diseases and a pharmaceutical composition comprising same. A protein or polynucleotide according to one aspect has excellent therapeutic effects i...  
WO/2023/004386A9
The present disclosure provides methods for treating Alzheimer's disease by subcutaneously administering a high volume and high dose of a brain targeting antibody or antigen-binding fragment thereof and provides compositions comprising a...  
WO/2024/016826A1
The present invention relates to the field of organic synthetic medicines, and in particular, to a 6-position substituted 3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide compound, having a general formula as follows: (I). The 6-positio...  
WO/2024/020170A1
Provided herein are compounds which can act agonists of the aryl hydrocarbon receptor (AHR). Further disclosed herein are methods for treating inflammatory and autoimmune diseases and disorders, such as diseases or disorders of the gastr...  
WO/2024/020091A1
A method of decreasing blood glial fibrillary acidic protein (GFAP) levels in a subject in need thereof includes administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor. Astroglia cells are the major and pe...  
WO/2024/016935A1
The present invention belongs to the field of functional emulsions. Disclosed is a method for improving the embedding rates of ginsenosides Rg3 and CK and the stability of a nanoemulsion. The method for improving the embedding rates of r...  
WO/2024/019957A1
Provided herein are compounds and compositions thereof for modulating S1P5. In some embodiments, the compounds and compositions are provided for treatment of neurological diseases.  
WO/2024/019908A1
Methods and compositions for treating or alleviating symptoms of selective mutism in a human subject with a serotonergic psychedelic agent alone or in combination with N-acetylcysteine are provided.  
WO/2024/019661A1
The present disclosure concerns a method of promoting the ubiquitination of MK2 protein, comprising contacting the MK2 protein with a compound of Formula (I) or a salt, solvate, stereoisomer or prodrug thereof. The present disclosure als...  
WO/2024/017227A1
Provided is a cannabinoid receptor compound as represented by formula I. The compound has a good ability to bind to the human CB2 receptor, and exhibits good agonistic activity and high selectivity on the CB2 receptor. Consequently, said...  
WO/2024/020156A1
Provided are compounds of the Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of EBP and in the treatment of a variety of EBP mediated conditions or diseases, such as multiple sclerosis.  
WO/2024/017858A1
The invention relates to novel compounds having the general formula (I) wherein R1, R2, X1, X2, X3 and W are as described herein, composition including the compounds and methods of using the compounds.  
WO/2024/019962A1
The present invention generally relates to compositions and methods useful for treating a brain injury such as stroke, optic neuropathy, traumatic brain injury, and cerebral palsy. The methods include administering HMCs obtained by in vi...  
WO/2024/020059A1
The present invention is directed to methods of treating Alzheimer's disease in a subject in need thereof. Also disclosed are methods of identifying novel compounds that may be useful in the treatment and prevention of Alzheimer's diseas...  
WO/2024/017855A1
The invention relates to novel compounds having the general formula (I) wherein R1, R2, R3, X and Y are as described herein, composition including the compounds and methods of using the compounds.  
WO/2024/017915A1
The present technology relates to a polypeptide comprising at least three immunoglobulin single variable domains (ISVDs). In particular, the present technology relates to a polypeptide comprising an optimized ISVD binding to fractalkine ...  
WO/2024/019026A1
The present invention provides a pharmaceutical composition containing a compound represented by formula (I), a salt thereof, or a solvate thereof. The present invention uses, as a disintegrant, a partially pregelatinized starch, carmell...  
WO/2024/019532A1
The present invention relates to a composition for preventing and ameliorating memory decline comprising lysophospholipids derived from marine life containing omega-3 fatty acids and, more specifically, to a composition for preventing an...  
WO/2024/019489A1
The present invention relates to an AAV vector and cell-penetrating peptide fusion platform and a pharmaceutical composition for the prevention or treatment of degenerative brain diseases, including same. The platform overcomes the limit...  
WO/2024/017257A1
The present application relates to an aromatic substituent-containing heteroaryl- or phenyl-imidazole compound, and a stereoisomer, hydrate, solvate, pharmaceutically-acceptable salt or prodrug thereof. The present application also relat...  
WO/2024/017293A1
The present application provides a use of mitoxantrone hydrochloride liposome in treatment of neuromyelitis optica spectrum disorders. The present application further provides a method for treating neuromyelitis optica spectrum disorders...  
WO/2024/017366A1
Provided are a compound of formula (I) having an effect of regulating and controlling the activity of 15-PGDH, a stereoisomer, a tautomer or a form of a mixture thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof...  
WO/2024/020572A1
Use of particular biomarkers in biological samples with altered expression or activity levels to diagnose, prognose, and treat post-traumatic stress disorder (PTSD) in individuals, and further to select individuals who would benefit from...  
WO/2024/019959A1
Compositions for inhibiting lipoxygenase enzymes (e.g., human epithelial 12/15-lipoxygenase (12/15-LOX) are provided. Compositions according to certain embodiments include a first solvent, a second solvent and a lipoxygenase inhibitor. I...  
WO/2024/017857A1
The invention relates to novel compounds having the general formula I wherein R1, R2, X1, X2,X3 and W are as described herein, composition including the compounds and methods of using the compounds.  
WO/2024/017990A1
Inventors have used FXYD7 knock-out mouse line and DRG-specific conditional Knock-out mice to demonstrate that the constitutive or DRG-specific knock-out of the FXYD7 gene specifically alleviate mechanical chronic pain induced by periphe...  
WO/2024/015286A1
Provided herein are methods of treating a neurological disease or disorder (e.g., ALS) comprising administering PIKFyve inhibitor (e.g., any PIKfyve inhibitors known or described herein, including but not limited to apilimod, APY0201, an...  
WO/2024/012317A1
A composition for resisting aging, and a use thereof or a method therefor. The pharmaceutical composition comprises a therapeutic agent X or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipien...  
WO/2024/012503A1
The present invention provides a composition based on three factors and used for restoring viability of cells, tissue, or organs of a subject, and a method for using the composition to restore viability of the cells, tissue, or organs of...  
WO/2024/013395A1
The application relates to pyrrolotriazine and imidazotriazine derivatives of the general formula (I) for the treatment, alleviation or prevention of a group of diseases, disorders and abnormalities which are responsive to the modulation...  
WO/2024/012551A1
The present invention relates to a class of deuterium-substituted pyridazine benzothiophene compounds and the use thereof.  
WO/2024/014986A1
The invention relates to a magnesium complex of the peptide HAEE described by the formula [Mg(HAEE)]mXn, where Mg is a doubly-charged magnesium (II) cation, m=1 for singly-charged and doubly-charged anions, m=3 for triply-charged anions,...  
WO/2024/013505A1
The present invention relates to compositions and kits comprising: • (i) gaboxadol, or a pharmaceutically acceptable sal t thereof; and • (ii) ibudilast, or a pharmaceutically acceptable salt thereof. The compositions and kits are us...  
WO/2024/015797A1
The present disclosure relates to peptide having a sequence comprising: Z1X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15-NH2 (SEQ ID NO: 1), And to their isomers, pharmaceutically acceptable salts, or prodrugs thereof, methods of use, and methods ...  
WO/2024/015503A1
Provided are compounds of the Formula (I) or pharmaceutically acceptable salts thereof, which are useful for the inhibition of EBP and in the treatment of a variety of EBP mediated conditions or diseases, such as multiple sclerosis.  
WO/2024/011316A1
Compound of Formula (II) is provided: (II) A crystalline form of the compound of Formula (II) is provided. The compound of Formula (II), and crystalline form thereof can be used for the treatment of several conditions linked to the inhib...  
WO/2024/014980A1
The invention relates to a monosubstituted or disubstituted potassium salt of the peptide HAEE, where HAEE is a synthetic peptide that is acetylated at the N-terminus and amidated at the C-terminus and has the amino acid sequence His-Ala...  
WO/2024/013567A1
The disclosure is directed to compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. The disclosure is also directed to pharmaceutical compositions containing compounds of Formula (I) and pharmaceutically ac...  
WO/2024/013393A1
The present disclosure relates to a method of increasing nicotinamide mononucleotide (NMN) and/or nicotinamide adenine dinucleotide (NAD+) in the gut of a subject by administering a combination comprising at least one Bifidobacterium sp....  
WO/2024/013523A1
This invention relates to pharmaceutically acceptable ergoline and tryptamine-based compounds (e.g. analogues, prodrugs and salts thereof). In particular, though not exclusively, the invention relates to formulations and uses of the same...  
WO/2024/012532A1
Provided is a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof. In addition, further provided are a method for preparing the compound and a pharmaceutically acceptable salt thereof, and the use thereof...  
WO/2024/012600A1
Provided in the present invention is a biomarker miR-25802 cluster for inflammation-related diseases, wherein the miR-25802 cluster can also be used as a target for treating inflammation-related diseases.  
WO/2024/013563A1
Disclosed herein are drug conjugates comprising targeting moieties conjugated to drug molecules, wherein the targeting moieties bind to receptors expressed on Schwann cells to mediate targeted delivery of the drug conjugate to the Schwan...  

Matches 251 - 300 out of 115,935